Abstract library

7 results for "Kebebew".
#1769 Minimal Risk of Persistent or Recurrent Hypoglycemia after MEN1-Related Insulinoma Surgery. A Large International Cohort Study
Introduction: Current literature states that 15-30% of the MEN1 patients suffer from hypoglycemia after insulinoma surgery.
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: Drs. Sjoerd Nell
Authors:
Keywords: MEN1
#1853 24 Hour Urinary 5-Hydroxyindoleacetic Acid (5HIAA) and Vasoactive Intestinal Peptide (VIP) Doubling-Times (DTs) Predict Disease-Specific Mortality (DSM) in Patients with Neuroendocrine Tumors (NETs)
Introduction: New clinical prognostic tools are needed in order to select patients with NETs that are at higher risk of DSM. Biochemical biomarker DT is used clinically for prognosis prediction in several solid malignancies
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: MD Amit Tirosh
Authors:
#1854 VHL Genotype Is Associated with Pancreatic Neuroendocrine Tumors (PNETs) Phenotype in Patients with Von Hippel-Lindau Disease (VHLD)
Introduction: 8-20% of patients with VHLD develop PNETs. However, there are no markers for PNETs progression in VHLD patients. The type of mutation in VHL gene is associated with clinical phenotype of VHLD.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Amit Tirosh
Authors:
Keywords: VHL, mutation, prognosis
#1855 Total 68Ga-DOTATATE-Avid Tumor Volume (TV) Predicts Progression-Free Survival (PFS) and Disease-Specific Mortality (DSM) in Patients with Neuroendocrine Tumors (NETs)
Introduction: Patients with NETs have divergent survival, even when having the same site of primary tumor, tumor stage and grade. 68Ga-DOTATATE PET/CT has emerged as a sensitive imaging modality for detecting NETs.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Amit Tirosh
Authors:
#1857 Association between Neuroendocrine Tumors (NETs) Biomarkers and Tumor Burden Based on Total 68Ga-DOTATATE-Avid Tumor Volume (TV) Measurements
Introduction: No study has yet assessed the utility of biochemical biomarkers for evaluating NET burden using 68Ga-DOTATATE PET/CT.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: MD Amit Tirosh
Authors:
Keywords: PET burden
#2219 24 Hour Urinary 5-Hydroxyindoleacetic Acid Levels in Patients with Non-Functioning Pancreatic Neuroendocrine Tumors
Introduction: The secretion of urinary 5-Hydroxyindoleacetic Acid (u5-HIAA) by non-functioning PNETs (NF-PNET) has rarely been reported, and the data on the association between u5-HIAA levels and disease burden is scant.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Dr Amit Tirosh
Authors:
#2234 High Rate of Copy-Number Alterations in Gastrointestinal and Pancreatic Neuroendocrine Tumors with Unidentified Driver Mutations
Introduction: The driving genetic alteration leading to neuroendocrine tumor (NET) development has been reported for primary tumors of pancreatic origin, but not for metastases. Moreover, even for primary tumor a significant “dark matter” remains to be explored.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Amit Tirosh
Authors: